'T'he therapeutic approach to asthma can be systematized from a practical point of view, as follows: 1. symptomatic treatment of respiratory obstruction, a) acute, and b) chronic; 2. prophylactic treatment of asthma; 3. specific treatment (immunotherapy). The way the different therapeutic resources are applied differs from patient to patient and constitutes what could be defined as the therapeutic strategy of asthma.
volume in one second (FEVj) <1,000 ml or a peak expiratory flow (PEFR) of <150 L/min are considered to have acute obstruction. If they are also dyspneic, pale, sweating, using the accessory respiratory muscles and speaking a monosyllabic language, we consider their obstructive disease severe, an assessment that is further strengthened by the presence of tachycardia, cyanosis and pulsus paradoxus. If the FEV, is <700 ml and PEFR is =sl00 L/min, the patient should be hospitalized, and if the arterial Pa02 falls below 60 mm Hg, we will consider admission to the intensive care unit. Depending upon the behavior of the arterial Pa02, PaC02 and pH, respiratory failure may be seen in the asthmatic patient 3 with progressive deterioration. Mechanical ventilation may become necessary.
Treatment of Severe Acute Asthma
Due to the intensity and severity of airway obstruction, the use of intravenous medication is mandatory, applying: a) anti-inflammatory measures (corticosteroids), b) bronchodilators (aminophylline, (32 sympathomimetics), and c) hydration (5 percent glucose solution). Other measures include correction of hypoxia (oxygen), expectorants and support measures 
Treatment of Acute Moderate Asthma
The symptomatic treatment of acute moderate asthma is done on the basis of a step-wise approach. In adults, we initially use epinephrine at 1:1,000 dilution (or terbutaline or salbutamol), 0.4-0.5 ml subcutane- 
Treatment of Chronic Asthma
The wide therapeutic armamentarium available (Table 4), must be employed rationally, graduating its use in relation to the type, severity and pattern of the disease. With frequent episodes of bronchospasm it is important to consider a prophylactic strategy ( Table 5) .
Treatment of Slight Chronic Asthma
Only one bronchodilator drug will be recommended, either a |32 selective agonist, or a long-acting theophylline, 9 when the symptoms are concentrated at a particular time (nocturnal or morning dipping); or twice a day, when the symptoms, although slight, have a continuous distribution. In small children, we prefer oral administration, using either a rapid or sustainedreleased theophylline, or a t32 selective agonist syrup.
Treatment of Moderate Chronic Asthma
We generally use a combination of a j$2 selective sympathomimetic (orally tid or 2 puffs of aerosol qid), and a sustained-release theophylline, administered every 8 to 12 hours, depending upon the initial serum theophylline value (optimal range 10-20 (xg/ml).
If this initial approach does not control the disease, we add an inhaled corticosteroid (2 puffs qid). Following a widely recommended "scalator" procedure, 10 if we still fail to control the disease, we use a short course of oral corticosteroids, at an initial dose of 1-2 mg/kg bodyweight (average 60 mg for an adult), decreasing 5 mg every two days, to stop in 14 days. In patients, where we know the annual evolution of symptoms, the prophylactic use of cromolyn sodium (1 capsule of 20 mg qid), or a combination of a B2 sympathomimetic and ipratropium aerosol (2 puffs qid) should be considered. In patients with a clear extrinsic allergic etiology, it will be worthwhile to start a specific immunotherapy program with periodic injections.
Treatment of Severe Chronic Asthma
In general, we start with three drugs: (1) p2 selective sympathomimetic, preferably by aerosol every 6 hours, (2) beclomethasone aerosol (alternatively: ipratropium associated with a (32 agonist) and (3) oral theophylline (sustained release). There are combined forms of a selective (32 agonist, fenoterol plus ipratropium bromide (Berodual or Berodul), and salbutamol with beclomethasone (Ventide), which facilitate combined therapy. The oral theophylline is given every 8-12 hours, adjusting it based on age (more in children, less in patients over 60 years old), smoking habits (higher dose), and intercurrent diseases (less needed during pneumonia, cardiac failure, cor pulmonale, and liver disease).
If we fail in controlling the bronchial obstruction with the above, we proceed to the use of oral corticosteroids, associated with aerosolized beclomethasone. The use of oral corticosteroids will be limited to bring the acute exacerbation to a more stable stage.
If the severe symptoms reappear after eliminating the oral corticosteroid, the patient is considered corticosteroid-dependent, fortunately a rare condition. In this situation, alternate-day therapy is preferred to try to avoid adrenal suppression. 
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Treatment of Bronchial Asthma in Latin America (Edgardo Carrasco)
SPECIFIC TREATMENT OF ASTHMA
Finally, in a reduced group of asthmatic patients, those in the atopic extrinsic allergic group (about 40-60 percent of the total), one could offer the specific treatment of immunotherapy. After an accurate etiologic study, based on history, prick cutaneous tests, and in doubtful cases RAST and bronchial provocation tests, we could decide to start immunotherapy, mainly in patients sensitized to pollens, house dust, dermatophagoides and molds. In general, in Latin America, "vaccines" for food allergens are not used; however, a small group of specialists still use bacterial vaccines, in spite of its doubtful benefit.
